search
Back to results

Broad Band Light for the Treatment and Prevention of Senile Purpura

Primary Purpose

Senile Purpura, Bateman's Purpura

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Broad Band Light (BBL)
Sponsored by
Siperstein Dermatology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Senile Purpura focused on measuring skin atrophy, broad band bight, ecchymosis, collagen, elastin, RNA

Eligibility Criteria

22 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged >22
  • In good general health as evidenced by medical history
  • Ecchymosis greater than 1cm on each arm for the group with senile purpura

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Subjects with a history of any arm swelling
  • Subjects with allergies to light
  • Subjects with auto-immune skin conditions such as lupus, or vitiligo
  • Subjects using topical retinol within the last 3 months
  • Subjects with any scheduled laser, light, or surgical procedures on the arm during the study
  • Subjects unwilling or unable to keep their arms still during digital pictures
  • Subjects who are pregnant or nursing
  • Subjects with a history of herpes simplex or zoster on their arms
  • Subjects with current skin infections, tumors, or dermatitis on the arm
  • Subjects with allergies to lidocaine
  • Subjects with a history of keloid formation
  • Subjects with a history of a bleeding disorder
  • Subjects with allergies to adhesives

Sites / Locations

  • Siperstein Dermatology Group

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

BBL Left

BBL Right

Arm Description

Left arm selected to be treated with BBL, right arm not treated

Right arm selected to be treated with BBL, left arm not treated

Outcomes

Primary Outcome Measures

The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions
The number of purpuric lesions 30 days after the last treatment will be subtracted from the number of purpuric lesions at baseline
The Change in Total Square Size of Purpuric Lesions From Baseline to 30 Days After the Last Treatment
The size of the purpuric lesions will be measured by multiplying the height by the width in cm of each lesion and totaling the total cm2 area for each lesion on each arm. Then the total square area 30 days after the last treatment will be subtracted from the total square area at baseline.

Secondary Outcome Measures

Epidermal Thickness 1 Day After the Fourth BBL Treatment
Measurement of epidermal thickness in um as measured by H&E stained sections using the AxionVision image analysis software based on slides from biopsies taken from the subjects 1 days after their last treatment.

Full Information

First Posted
September 22, 2018
Last Updated
April 10, 2021
Sponsor
Siperstein Dermatology
Collaborators
University of Miami
search

1. Study Identification

Unique Protocol Identification Number
NCT03690375
Brief Title
Broad Band Light for the Treatment and Prevention of Senile Purpura
Official Title
A Prospective, Randomized, Split-Arm Pilot Study Investigating the Efficacy and Safety of Sciton's Broad Band Light for Improving the Clinical Signs of Senile Purpura
Study Type
Interventional

2. Study Status

Record Verification Date
November 2019
Overall Recruitment Status
Completed
Study Start Date
August 27, 2018 (Actual)
Primary Completion Date
October 15, 2019 (Actual)
Study Completion Date
November 11, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Siperstein Dermatology
Collaborators
University of Miami

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
There will be five subjects over the age of 65, each with at least one ecchymotic lesion on each arm measuring at least one cm, and five control subjects under the age of 35, both who will be randomized to undergo 4 Sciton Broad Band Light (BBL) treatments on either their left or right arm one week apart. Subjects will fill out questionnaires, have pictures of their lower arms taken, and will be graded and measured by evaluators regarding the number and size of their ecchymoses as well as side effects such as blistering, pain, erythema, and swelling. One day after their 4th treatment on each arm, subjects will have biopsies done to be analyzed for changes in histology and gene expression. The subjects will follow up 1 month after their last treatments for final pictures of their lower arms and evaluations.
Detailed Description
This will be a single center, prospective, split-arm clinical study in which subjects will be randomized to which arm will be treated with Sciton's broad band light (BBL) treatment. All subjects will have their arms shaved prior to the procedure and cleaned thoroughly with alcohol. After the procedure a zinc-based sunscreen will be applied to both arms. Before each of the four treatments, and 1 month after the last treatment, the subjects' number and square area of ecchymoses will be measured by an evaluator and photographs will be taken. Side effects will be measured the same day as the treatment as well as 1 day, 2 days, and 7 days after the first treatment. A final assessment will be done by taking two skin biopsies from the subjects with senile purpura, one on treated skin and one on untreated skin, and one skin biopsy on untreated skin in the younger controls. The skin specimens will be bisected and one half will be submerged immediately in 10x volumes of formalin while the other half of the biopsy will be submerged immediately in 10x volumes of RNAlater (Thermo Fisher Scientific, Waltham, MA). These specimens will then be coded and sent to blinded evaluators that will embed half in paraffin sections and then stain them with hematoxylin and eosin (H&E), von Giesen and or periodic acid-Schiff (PAS). Epidermal thickness will be measured on H&E-stained sections using the AxioVision image analysis software (Carl Zeiss Microimaging, Thornwood, NY). The epithelial thickness may vary from area to area within the biopsy. The thickness of the epithelium in µm will be measured at 6 points in each biopsy and averaged. Von Giesen-stained sections will be examined for elastosis, and PAS-stained sections will be examined for collagen. Total RNA will be extracted using TRIzol Reagent (Thermo Fisher Scientific, Waltham, MA) and the RNeasy mini kit (Qiagen, Valencia, CA). RNA will be reverse transcribed using qScript™ cDNA Synthesis Kit (QuantaBio, Beverly, MA). Real-time qPCR reactions will be carried out using PerfeCTa SYBR® Green SuperMix (QuantaBio, Beverly, MA) in triplicates. Gene expression levels will be normalized to a housekeeping gene, and analyzed using t test of means and SEM. Potential analysis include various biomarkers for dermal remodeling (e.g., collagen type I, elastin), epidermal differentiation (e.g., keratin 1, filaggrin), and vascular changes (e.g., endothelin, Ang).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Senile Purpura, Bateman's Purpura
Keywords
skin atrophy, broad band bight, ecchymosis, collagen, elastin, RNA

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BBL Left
Arm Type
Experimental
Arm Description
Left arm selected to be treated with BBL, right arm not treated
Arm Title
BBL Right
Arm Type
Experimental
Arm Description
Right arm selected to be treated with BBL, left arm not treated
Intervention Type
Device
Intervention Name(s)
Broad Band Light (BBL)
Intervention Description
Sciton's BBL treatment using a new protocol that utilizes a 590nm, 560nm, and skintyte filter
Primary Outcome Measure Information:
Title
The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions
Description
The number of purpuric lesions 30 days after the last treatment will be subtracted from the number of purpuric lesions at baseline
Time Frame
51 days (Treatments done every 7 days starting on Day 0 and ending on Day 21, then the final outcome was measured 30 days after the last treatment)
Title
The Change in Total Square Size of Purpuric Lesions From Baseline to 30 Days After the Last Treatment
Description
The size of the purpuric lesions will be measured by multiplying the height by the width in cm of each lesion and totaling the total cm2 area for each lesion on each arm. Then the total square area 30 days after the last treatment will be subtracted from the total square area at baseline.
Time Frame
51 Days (30 days after the final treatment at Day 21)
Secondary Outcome Measure Information:
Title
Epidermal Thickness 1 Day After the Fourth BBL Treatment
Description
Measurement of epidermal thickness in um as measured by H&E stained sections using the AxionVision image analysis software based on slides from biopsies taken from the subjects 1 days after their last treatment.
Time Frame
22 days (1 day after final treatment at day 21)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Provision of signed and dated informed consent form Stated willingness to comply with all study procedures and availability for the duration of the study Male or female, aged >22 In good general health as evidenced by medical history Ecchymosis greater than 1cm on each arm for the group with senile purpura Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: Subjects with a history of any arm swelling Subjects with allergies to light Subjects with auto-immune skin conditions such as lupus, or vitiligo Subjects using topical retinol within the last 3 months Subjects with any scheduled laser, light, or surgical procedures on the arm during the study Subjects unwilling or unable to keep their arms still during digital pictures Subjects who are pregnant or nursing Subjects with a history of herpes simplex or zoster on their arms Subjects with current skin infections, tumors, or dermatitis on the arm Subjects with allergies to lidocaine Subjects with a history of keloid formation Subjects with a history of a bleeding disorder Subjects with allergies to adhesives
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robyn Siperstein, MD
Organizational Affiliation
Siperstein Dermatology/ University of Miami
Official's Role
Study Director
Facility Information:
Facility Name
Siperstein Dermatology Group
City
Boynton Beach
State/Province
Florida
ZIP/Postal Code
33472
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29336034
Citation
Faucz LL, Will SE, Rodrigues CJ, Hesse H, Moraes AC, Maria DA. Quantitative evaluation of collagen and elastic fibers after intense pulsed light treatment of mouse skin. Lasers Surg Med. 2018 Jan 16. doi: 10.1002/lsm.22782. Online ahead of print.
Results Reference
background
PubMed Identifier
10971556
Citation
Bitter PH. Noninvasive rejuvenation of photodamaged skin using serial, full-face intense pulsed light treatments. Dermatol Surg. 2000 Sep;26(9):835-42; discussion 843. doi: 10.1046/j.1524-4725.2000.00085.x.
Results Reference
background
PubMed Identifier
21242389
Citation
McKenzie NE, Saboda K, Duckett LD, Goldman R, Hu C, Curiel-Lewandrowski CN. Development of a photographic scale for consistency and guidance in dermatologic assessment of forearm sun damage. Arch Dermatol. 2011 Jan;147(1):31-6. doi: 10.1001/archdermatol.2010.392.
Results Reference
background
PubMed Identifier
19289681
Citation
DeFatta RJ, Krishna S, Williams EF 3rd. Pulsed-dye laser for treating ecchymoses after facial cosmetic procedures. Arch Facial Plast Surg. 2009 Mar-Apr;11(2):99-103. doi: 10.1001/archfacial.2008.538.
Results Reference
background
PubMed Identifier
28858925
Citation
Brauer JA, Farhadian JA, Bernstein LJ, Bae YS, Geronemus RG. Pulsed Dye Laser at Subpurpuric Settings for the Treatment of Pulsed Dye Laser-Induced Ecchymoses in Patients With Port-Wine Stains. Dermatol Surg. 2018 Feb;44(2):220-226. doi: 10.1097/DSS.0000000000001255.
Results Reference
background
PubMed Identifier
22931923
Citation
Chang AL, Bitter PH Jr, Qu K, Lin M, Rapicavoli NA, Chang HY. Rejuvenation of gene expression pattern of aged human skin by broadband light treatment: a pilot study. J Invest Dermatol. 2013 Feb;133(2):394-402. doi: 10.1038/jid.2012.287. Epub 2012 Aug 30. Erratum In: J Invest Dermatol. 2013 Jun;133(6):1691.
Results Reference
background
PubMed Identifier
11870785
Citation
Prieto VG, Sadick NS, Lloreta J, Nicholson J, Shea CR. Effects of intense pulsed light on sun-damaged human skin, routine, and ultrastructural analysis. Lasers Surg Med. 2002;30(2):82-5. doi: 10.1002/lsm.10042.
Results Reference
background

Learn more about this trial

Broad Band Light for the Treatment and Prevention of Senile Purpura

We'll reach out to this number within 24 hrs